Revised criteria for the diagnosis of mild cognitive impairment (MCI) could compromise the diagnosis of Alzheimer disease (AD) dementia, according to an analysis published online Feb. 6 in Archives of Neurology.
The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium has released biomarker data from studies intended to improve the ability to diagnose and measure the progression of Alzheimer’s disease.
This article discusses the recent updates in Alzheimer’s detection using amyloid PET radiotracer 18F-flutemetamol, proteins in the cerebrospinal fluid and blood.
Compared with changes in biomarkers, changes in cognitive abilities appear to be stronger predictors of whether an individual with mild cognitive impairment (MCI) will develop Alzheimer’s disease, based on research published in the September issue of Archives of General Psychiatry.
18F-FDG PET may provide a quantitative measure to detect progression from mild cognitive impairment (MCI) to Alzheimer's disease (AD), and could offer a mechanism to streamline clinical trials, according to a study published in this month's
Journal of Nuclear Medicine.
The automated measurement of temporoparietal brain region volumes is a highly accurate predictor of memory loss in healthy elderly persons, indicating that these underlying characteristics could help clinicians identify likely cases of pre-clinical Alzheimer’s and enable them eventually to prevent the disease’s progression, according to an article published in the June issue of
Radiology.
RSS 
